Patent ID: 11931414
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 14:
15. The Ligand-Drug Conjugate compound of claim 10, wherein the Ligand Unit is an intact antibody or antigen binding fragment of an antibody, thereby defining an antibody Ligand Unit of an antibody drug conjugate (ADC), wherein the moiety targeted by the antibody Ligand Unit is an accessible cell-surface antigen of abnormal cells that is capable of cellular internalization when bound to ADC compound and is present in greater copy number on the abnormal cells in comparison to normal cells distant from the site of the abnormal cells,
or wherein the Ligand Unit is a cognate ligand of an accessible cell-surface receptor on abnormal cell that is capable of cellular internalization when bound to a Ligand Drug Conjugate compound of the composition, and wherein the receptor is present in greater copy number on the abnormal cells in comparison to normal cells distant from the site of abnormal cells,
or wherein the Ligand Unit is an antibody, thereby defining an antibody Ligand Unit of an antibody drug conjugate (ADC), wherein the moiety targeted by the antibody Ligand Unit is an accessible cell-surface antigen of a vascular epithelial cell in the vicinity of abnormal cells, wherein said antigen is capable of cellular internalization of bound ADC and is present in greater copy number on said cells in comparison to normal epithelial cells distant from the site of the abnormal cells.